AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has an option agreement with Velo Bio LLC to acquire the rights to digoxin immune fab, a polyclonal antibody, which is in Phase IIb/IIIa trial for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, offer for sale, and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-498-3300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$609.95 million
Profitability
Miscellaneous
Employees762
OptionableOptionable
AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions
What is AMAG Pharmaceuticals' stock symbol?
AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."
How were AMAG Pharmaceuticals' earnings last quarter?
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced its quarterly earnings results on Thursday, November, 1st. The specialty pharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.77) by $1.11. The specialty pharmaceutical company earned $122.20 million during the quarter, compared to the consensus estimate of $118.23 million. AMAG Pharmaceuticals had a negative net margin of 6.98% and a negative return on equity of 13.65%. The business's quarterly revenue was down 1.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($4.31) EPS. View AMAG Pharmaceuticals' Earnings History.
When is AMAG Pharmaceuticals' next earnings date?
What guidance has AMAG Pharmaceuticals issued on next quarter's earnings?
AMAG Pharmaceuticals issued an update on its FY 2018 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $471-476 million, compared to the consensus revenue estimate of $490.94 million.AMAG Pharmaceuticals also updated its Q4 2018 guidance to EPS.
What price target have analysts set for AMAG?
10 brokerages have issued twelve-month price targets for AMAG Pharmaceuticals' shares. Their predictions range from $18.00 to $24.65. On average, they expect AMAG Pharmaceuticals' share price to reach $20.9650 in the next twelve months. This suggests a possible upside of 23.0% from the stock's current price. View Analyst Price Targets for AMAG Pharmaceuticals.
What is the consensus analysts' recommendation for AMAG Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AMAG Pharmaceuticals.
What are Wall Street analysts saying about AMAG Pharmaceuticals stock?
Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "AMAG's Feraheme currently competes with IV iron replacement therapies including Venofer, Injectafer, Ferrlecit and their generic versions among others. Feraheme may also face competition from generic IV iron replacement products that could further limit sales. Currently, AMAG is involved in a patent litigation with Novartis’ generic arm, Sandoz, for Feraheme. However, in June 2018, the FDA accepted AMAGs new drug application for bremelanotide and the company is initiating programs to educate healthcare providers about diagnosing hypoactive sexual desire disorder. Loss estimates of the cmpany have remained stable ahead of the Q3 earnings. " (10/5/2018)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate the Neutral rating and adjust our PT to $18 (from $17) for AMAG stock. With the commercial potential of Intrarosa still unproven and the approvability of bremelanotide unknown, we believe investors will view the Makena franchise as the most significant supporter of share price value, particularly now that the CBR business is being divested. We suppose a bullish outlook could prevail over the near- to intermediate-term if Makena holds its own and no evidence emerges that Intrarosa or bremelanotide could disappoint expectations. We believe that the set up for 2019 has to be decidedly positive for the stock to perform well over the next 12-18 months absent, of course, transformational business activities." (8/3/2018)
Has AMAG Pharmaceuticals been receiving favorable news coverage?
Press coverage about AMAG stock has been trending extremely positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. AMAG Pharmaceuticals earned a news sentiment score of 4.1 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are some of AMAG Pharmaceuticals' key competitors?
Some companies that are related to AMAG Pharmaceuticals include Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Endo International (ENDP), Arena Pharmaceuticals (ARNA), Opko Health (OPK), Mirati Therapeutics (MRTX), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Innoviva (INVA), Endocyte (ECYT), AnaptysBio (ANAB), Xencor (XNCR), Insmed (INSM) and Madrigal Pharmaceuticals (MDGL).
Who are AMAG Pharmaceuticals' key executives?
AMAG Pharmaceuticals' management team includes the folowing people:
- Dr. William K. Heiden, CEO, Pres & Director (Age 58)
- Mr. Edward H. Myles, Exec. VP & CFO (Age 46)
- Mr. Joseph D. Vittiglio, Exec. VP of Legal Affairs and Quality, Gen. Counsel & Sec. (Age 46)
- Dr. Julie Krop, Exec. VP of Devel. & Chief Medical Officer (Age 52)
- Mr. Nicholas Grund, Exec. VP & Chief Commercial Officer (Age 48)
Who are AMAG Pharmaceuticals' major shareholders?
AMAG Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.04%) and Louisiana State Employees Retirement System (0.04%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals.
Which institutional investors are selling AMAG Pharmaceuticals stock?
AMAG stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. Company insiders that have sold AMAG Pharmaceuticals company stock in the last year include Joseph Vittiglio and William K Heiden. View Insider Buying and Selling for AMAG Pharmaceuticals.
Which institutional investors are buying AMAG Pharmaceuticals stock?
How do I buy shares of AMAG Pharmaceuticals?
Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AMAG Pharmaceuticals' stock price today?
One share of AMAG stock can currently be purchased for approximately $17.05.
How big of a company is AMAG Pharmaceuticals?
AMAG Pharmaceuticals has a market capitalization of $588.84 million and generates $609.95 million in revenue each year. The specialty pharmaceutical company earns $-199,220,000.00 in net income (profit) each year or ($5.71) on an earnings per share basis. AMAG Pharmaceuticals employs 762 workers across the globe.
What is AMAG Pharmaceuticals' official website?
How can I contact AMAG Pharmaceuticals?
AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]
MarketBeat Community Rating for AMAG Pharmaceuticals (NASDAQ AMAG)
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days.
